Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Status:
Completed
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and
immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris